Want to see ADIL full AI Analyst Report?
Top Page
Adial Pharmaceuticals
(NASDAQ:ADIL)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▼(-32.66% Downside)
Action:Upgraded
Date:10/02/26
The score is primarily weighed down by weak financial performance (pre-revenue, sharply wider losses, ongoing cash burn, and negative equity). Corporate events add meaningful downside risk due to Nasdaq listing/compliance uncertainty and governance transition. Technicals are also weak in the near term, while valuation provides limited support given negative earnings and no dividend yield data.
Positive Factors
Minimal debt burden
Essentially no debt reduces refinancing exposure and interest-rate pressure, preserving more flexibility for clinical development and corporate priorities. This is a durable balance-sheet advantage, although it does not offset the company’s broader capital needs and negative equity position.
Negative Factors
Pre-revenue development profile
The company remains dependent on clinical and regulatory progress because it has no reported commercial revenue. The sharp increase in losses raises execution risk and means future value depends heavily on successful development, approval, and eventual commercialization of its pipeline.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal debt burden
Essentially no debt reduces refinancing exposure and interest-rate pressure, preserving more flexibility for clinical development and corporate priorities. This is a durable balance-sheet advantage, although it does not offset the company’s broader capital needs and negative equity position.
Read all positive factors
Adial Pharmaceuticals (ADIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.42M
Dividend YieldN/A
Average Volume (3M)42.90K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS Growth45.78%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.53
Shares Outstanding2,625,890
10 Day Avg. Volume30,441
30 Day Avg. Volume42,903
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap4.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-322.44K
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$11.00Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Adial Pharmaceuticals Business Overview & Revenue Model
Company Description
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its prim...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Adial has historically not generated meaningful recurring revenue from commercial product sales because its primary drug candidate(s) have been in development rather than approved and marketed. Its ab...
Adial Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -141.00 | 0.00 | 0.00 | -564.00 | 0.00 | 0.00 |
| EBITDA | -57.80M | -7.98M | -13.20M | -7.00M | -10.80M | -17.69M |
| Net Income | -57.80M | -7.98M | -13.20M | -7.00M | -12.73M | -19.42M |
Balance Sheet | ||||||
| Total Assets | 29.09M | 6.80M | 5.04M | 4.74M | 5.73M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 28.71M | 5.88M | 3.75M | 2.83M | 4.00M | 6.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 207.38K | 256.96K |
| Total Liabilities | 28.93M | 1.52M | 975.86K | 653.51K | 2.46M | 4.13M |
| Stockholders Equity | 156.00K | 5.28M | 4.07M | 4.08M | 3.28M | 3.51M |
Cash Flow | ||||||
| Free Cash Flow | -11.13M | -6.49M | -6.92M | 0.00 | -11.19M | -12.01M |
| Operating Cash Flow | -11.13M | -6.49M | -6.92M | -6.81M | -11.19M | -11.95M |
| Investing Cash Flow | 5.28M | 150.00K | 0.00 | 1.50M | 0.00 | -34.02K |
| Financing Cash Flow | 28.65M | 8.47M | 7.85M | 4.13M | 9.13M | 13.64M |
Adial Pharmaceuticals Technical Analysis
Negative
5.94
Price Trends
4.88
Negative
3.75
Positive
3.38
Positive
Market Momentum
-0.30
Positive
39.07
Neutral
12.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADIL, the sentiment is Negative. The current price of 5.94 is above the 20-day moving average (MA) of 4.36, above the 50-day MA of 4.88, and above the 200-day MA of 3.38, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 39.07 is Neutral, neither overbought nor oversold. The STOCH value of 12.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADIL.
Adial Pharmaceuticals Risk Analysis
Adial Pharmaceuticals disclosed 80 risk factors in its most recent earnings report. Adial Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adial Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $11.19M | -1.01 | -63.39% | ― | ― | 19.38% | |
42 Neutral | $2.77M | -0.15 | -181.45% | ― | ― | 68.91% | |
42 Neutral | $3.82M | -0.02 | -372.86% | ― | ― | 53.95% | |
41 Neutral | $10.42M | -0.24 | -1693.21% | ― | ― | 45.78% |
* Healthcare Sector Average
ADIL
Adial Pharmaceuticals
3.90
-5.35
-57.85%
KPRX
Kiora Pharmaceuticals
2.54
-0.18
-6.62%
MTNB
Matinas BioPharma
2.87
-24.65
-89.57%
ALZN
Alzamend Neuro
1.34
-0.86
-39.09%
CLDI
Calidi Biotherapeutics
1.03
-25.05
-96.05%
Adial Pharmaceuticals Corporate Events
Business Operations and StrategyDelistings and Listing ChangesShareholder Meetings
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision
Negative
Oct 2, 2026
Adial Pharmaceuticals reconvened its 2026 Annual Meeting of Stockholders on October 1, 2026 to address Proposals 3, 4, 5 and 6 but again postponed the vote because it had not yet received Nasdaq’s approval of its listing application. The mee...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Adial Shareholders Approve Key Proposals, Meeting Adjourned
Neutral
Sep 18, 2026
On September 17, 2026, Adial Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum representing 48.7% of outstanding common shares participated. Shareholders elected two Class II directors, ratified CBIZ CPAs P.C. as t...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
Neutral
Sep 16, 2026
Adial Pharmaceuticals disclosed that accounting treatment of Milestone Warrants linked to its June 2026 PIPE and note exchange had driven stockholders’ equity below Nasdaq’s continued and initial listing thresholds as of June 30, 2026....
Business Operations and StrategyRegulatory Filings and Compliance
Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
Neutral
Aug 25, 2026
On August 19, 2026, Adial Pharmaceuticals granted a stock option to purchase 307,814 shares of common stock to a new employee as a material inducement to join the company, with an exercise price of $5.76 per share and a ten-year term. The option, ...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder Meetings
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
Negative
Aug 21, 2026
On August 18, 2026, Adial Pharmaceuticals received a notice from Nasdaq that it no longer meets the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, and also fails to qualify under alt...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Adial Pharmaceuticals Plans Major Leadership and Board Transition
Negative
Aug 13, 2026
As of August 10, 2026, Adial Pharmaceuticals announced that, contingent on stockholder approval of certain proposals at its 2026 annual meeting, President and CEO Cary Claiborne and CFO Vinay Shah are expected to be terminated and receive contract...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.